Mendoza, NicolasDiaz-Ropero, Maria PazAragon, MiguelMaldonado, VicenteLlaneza, PlacidoLorente, JuanMendoza-Tesarik, RaquelMaldonado-Lobon, JoseOlivares, MonicaFonolla, Juristo2025-01-072025-01-072019-03-16https://hdl.handle.net/10668/24991The purpose of this study was to evaluate the effect of two doses of D-chiro-inositol (DCI) in combination with Myo-inositol (MYO) in women with PCOS undergoing ICSI. This was a multicenter controlled, randomized, double-blind parallel group study with two MYO-DCI formulations for 12 weeks. The study group (SG) was administered 550 mg of MYO + 150 mg of DCI twice daily; the control group (CG) was administered 550 mg of MYO + 13.8 mg of DCI twice daily. The participants comprised 60 women with PCOS undergoing ICSI. At baseline, no differences were found between the two groups regarding age, BMI, HOMA-IR or testosterone levels. The pregnancy and live birth rates were significantly higher in the SG than in the CG (65.5 vs. 25.9 and 55.2 vs. 14.8, respectively) [risk ratio (RR) = 0.4; 95%CI (0.2, 0.79); p = .003 and RR = 0.27; 95%CI (0.10, 0.70); p = .002 respectively]. The risk of ovarian hyperstimulation syndrome (OHSS) was lower in the SG (3.44 vs. 18.5%, p = .07). The combination of MYO-DCI at high doses of DCI improves the pregnancy rates and reduces the risk of OHSS in women with PCOS undergoing ICSI.enAttribution-NonCommercial-NoDerivatives 4.0 Internationalhttp://creativecommons.org/licenses/by-nc-nd/4.0/-chiro-inositolICSIMyo-inositolpolycystic ovary syndromepregnancy rateAdolescentAdultBirth RateDose-Response Relationship, DrugDouble-Blind MethodDrug CompoundingFemaleFertilization in VitroHumansInfant, NewbornInfertility, FemaleInositolOvarian Hyperstimulation SyndromePolycystic Ovary SyndromePregnancyPregnancy RateSperm Injections, IntracytoplasmicYoung Adultresearch article30880505open access10.1080/09513590.2019.15766201473-0766https://www.tandfonline.com/doi/pdf/10.1080/09513590.2019.1576620?needAccess=true